The somatic mutations independently estimated by CRAVAT were H179R and G245C for TP53 and P750R for DNMT3A. Prospective application of this approach should be assessed in a future umbrella trial of lung cancer patients. The gene discussed is TP53; the disease is lung carcinoma.